Isosorbide-5-mononitrate 50 mg for the management of coronary aretry disease. In biphasic release formulation, 30% immediate release & 70% sustained release to provide risk adjusted protection with once daily dosage and nitrate free interval.
Isosorbide 5-mononitrate 50 mg in biphasic release formulation, 30% immediate release & 70% sustained release for risk adjusted protection.
Long term treatment of coronary artery disease. Prophylaxis of anginal attacks; post-treatment of myocardial infarction with persisting anginal symptoms; long term treatment of chronic congestive heart failure in combination with digitalis and/or diuretics; chronic cor pulmonale.
Headache (less frequent than with others) & subsides gradually upon continuing treatment).
Dosage and Administration
One to two capsules once daily.
In the Most recent Guidelines of the European Society of Cardiology (SCAD) for the management of Stable Coronary Aretry Disease (SCAD);
Nitrates were recommended for the relief of Angina/ Ischaemia.
Lipanthyl 300 is recommended for the treatment of hypercholesterolaemia (abnormally elevated levels of cholesterol in blood) and/or hypertriglyceridaemia (abnormally elevated levels of triglycerides).
As a global leader in biotechnology & cellular engineering, ProBioGen-Minapharm
As a continuation of Minapharm unique series of "Expert Panel",
The meeting was chaired by Prof. Abdel-Shakour EL MOHAMADY.
The Turning Point in Thrombosis Challenges
A Breakthrough technology for TREATMENT of Iron Deficiency Anemia
Risk Adjusted Protection...for Better Quality of Life
Stay connected, subscribe to our newsletter for news and updates.